Oye Olukotun, MD, MPH, FACC – President & CEO
Dr. Olukotun is President and CEO of Epigen Pharmaceuticals, Inc. as of June 2014 and a Managing Partner of CR Strategies, LLC, a medical products consulting company and the Vice Chairman of CardioVax Inc., a biotechnology company focused on developing innovative cardiovascular therapies. He is a co-founder of VIA Pharmaceuticals and served as the company’s Chief Medical Officer. He is a Board Certified Cardiologist and has 30 years of experience in clinical research and drug development in the pharmaceutical industry. He has published more than fifty articles in peer-reviewed scientific journals. Before CardioVax and VIA, he was Chief Medical Officer of Esperion Therapeutics, Inc., a cardiovascular drug development company, until its acquisition by Pfizer in 2004. From 1996 to 2000, Dr. Olukotun was Vice President of Medical and Regulatory Affairs and Chief Medical Officer of Mallinckrodt, Inc. Prior to joining Mallinckrodt, Dr. Olukotun spent fourteen years at Bristol-Myers Squibb Company, where he served as Vice President of two divisions focused on cardiovascular research, and was involved in the clinical development of several cardiovascular and lipid-regulating agents. Dr. Olukotun received his MD degree from Albert Einstein College of Medicine, New York and obtained a MPH degree from Harvard University School of Public Health, Boston. He is a Fellow of the American College of Cardiology as well as the American Heart Association. He is a member of the Board of Directors of the publicly traded biopharmaceutical companies: Nordion Inc. of Ottawa, Canada, and diaDexus Inc. of South San Francisco, CA. He was on the board of trustees of Delaware & Raritan (D&R) Greenway until 2012 and is currently on the board of trustees of Isles Inc. of Trenton, NJ.
Meg Helms, MBA – Business Development & Investor Relations
Meg Helms is Founder and President of Morgan Wallace Associates, LLC, a global strategic healthcare M&A consulting firm. In a variety of transaction-based assignments during her 31 year career with Johnson & Johnson (J&J), Meg successfully closed dozens of M&A transactions with deal values of up to $500 million. These included in and out-licensing agreements, privately and publicly held acquisitions, divestitures, co-development agreements, distribution, supply and licensing agreements and equity investments in start-up companies. She is particularly skilled in handling global transactions, most recently in Israel and China, and successfully completed many other transactions in Western Europe, Asia Pacific and the US. Meg holds an MBA from Washington University – St. Louis, and a BA from Rutgers University (Douglas College), New Brunswick, NJ. She is a member of BioNJ, Licensing Executives Society (LES), Healthcare Businesswomen’s Association (HBA) and Women’s Business Leaders in Healthcare (WBL).
Richard A. Reeves, MD, FRCPC, FACP – Clinical Development & Pharmacology
Richard A. Reeves is President of RAR Consulting, LLC, providing advice to small and large pharmaceutical companies on clinical, clinical pharmacology and regulatory interactions in the development of medications for human diseases. Prior to joining EpiGen, Dr. Reeves was Executive Director of the clinical pharmacology group responsible for cardiovascular, metabolics and neuroscience first-into-man compounds at Bristol-Myers Squibb from 2000-2008, and from 1992 to 2000 was Director in BMS’ Cardiovascular Clinical Research Department, in the Hypertension/renal Division. After completing his internal medicine residency, he completed fellowship training at the University of Pittsburgh and University of Toronto, and then joined the Department of Medicine, University of Toronto. He obtained his medical degree from McGill University, Montreal.
Martha Kelly, PhD – CMC, Medicinal Chemistry, & Intellectual Property
Martha Kelly is currently president of InveniRx, LLC, a consulting firm providing chemistry and project management services to biotech and pharmaceutical companies. Most recently, she served as Senior Director, Research & Product Development at Madrigal Pharmaceuticals, where she was managed the CMC, DMPK, toxicology and IP functions. Previously Dr. Kelly held positions of increasing responsibility at Locus Pharmaceuticals. She headed the medicinal chemistry and design group at Locus Pharmaceuticals and led teams in structure based drug design, hit to lead generation, lead optimization, API manufacture and Phase I clinical supply manufacture. Her experience includes managing the Locus chemistry patent portfolio and heading three successful partnered collaborative research projects. Prior to joining Locus, Dr. Kelly was at Rohm and Haas where she worked in both the Agricultural Chemicals process chemistry and discovery areas. Dr. Kelly received an A.B. in Chemistry from the College of the Holy Cross and a Ph.D. in Organic Chemistry from the University of Wisconsin-Madison. She was a postdoctoral fellow at the University of Geneva.
Laurie A. Myers, PhD, MBA – Commercial Development & Operations
Dr. Myers is a pharmaceutical executive, entrepreneur and scientist whose expertise traverses all aspects of branded specialty product life cycle management, from early discovery through product launch, including FDA submissions, P&L responsibilities and creating, disseminating and realizing global marketing plans. Dr. Myers therapeutic expertise includes oncology, cardiovascular disease/thrombosis with additional aptitude in infectious disease, neurologic disease, psychiatric disorders, asthma, urologic disease and women's health. She has played key role in drug development, marketing and commercialization for leading global pharmaceutical companies, including Novartis, Aventis, DuPont, Pfizer and Sanofi which included leadership positions in both R&D and marketing. Dr. Myers is a founding member of the Cingulate Therapeutics Board of Directors and contributes within two investor organizations; Mid Atlantic Bio Angels and Mid Atlantic Diamond Ventures. Dr. Myers earned her PhD in Toxicology from Rutgers Medical School/Rutgers School of Pharmacy in New Jersey and MBA in Pharmaceutical Marketing from St. Joseph’s University, Philadelphia, PA. Since 2011 she has served as Adjunct Professor at The College of New Jersey School of Business. She currently manages a private consulting company, Hallett Davis Strategic Group, LLC.
Edward Chiang – Clinical Operations & Project Management
Edward Chiang was worked for over 15 years in the area of clinical trial operations and management especially in the areas of medical imaging and cardiovascular. He has experience in both US and international settings. Edward was a Co-founder of Madrigal Pharmaceuticals and served as Head, Clinical Operations since the company inception in September 2011. Previously, Edward was one of the first 10 employees to join VIA Pharmaceuticals, and served as Associate Director of Clinical Operations from 2006 to 2011 managing Phase 2 cardiovascular trials. Prior to joining VIA, Edward was a project manager at Beacon Bioscience (now Icon Medical Imaging), a medical imaging CRO, working with clinical trial sponsors and study sites on the acquisition, processing, and review of medical images associated with clinical trials and a clinical trial manager at Bracco Diagnostics.
Rita A. Auld – CHRP Human Resources & Administration
Rita Auld has been a member of Senior Management teams for the past 15 years and has had direct responsibility for Human Resources, Administration and Facilities functions in companies as diverse as Accounting, Engineering, Manufacturing (semiconductor equipment as well as flexible sampling) Biotechnology and Specialty Pharmaceuticals. She was the Vice President, Human Resources and Administration for a Specialty Pharmaceutical company with a global operation before starting her own Consulting business in 2009. Rita has both an AS and BS in Business Administration from Thomas A. Edison State College and is a Certified Human Resources Professional from Cornell University. Auld Consulting LLC is certified as a Women Business Enterprise with the State of New Jersey.
David López – Analyst & Webmaster
David López is currently pursuing a BS in Management Science and Engineering, with a concentration in Organization, Technology, and Policy at Stanford University. He has worked as an analyst for the Research & Development and Marketing Divisions at an international nonprofit organization and has had direct responsibility with the CEO and COO regarding data research, data analysis, formal research writing, consulting, and presentation. He is the Operations Manager of the Ram's Head Theatrical Society, serving as the Vice President of the Executive Staff and Board of Directors. He also works as an Assistant to the Administrative Staff at the Stanford University Department of Philosophy during the academic year. He has eight years of vocal and theatrical performance experience and is heavily involved with the Stanford Fleet Street Singers, the Stanford Chamber Chorale, and the Ram's Head Theatrical Society. He is also a Finance Analyst with the Charles H. Blyth Fund, an investment management group, an Finance Associate with the Stanford Pre-Business Association, and has held a community leadership position with the Stanford LGBT Resource Center.